REGENXBIO 2017 AAV Gene Therapy Corporate Presentation

REGENXBIO is a leader in AAV gene therapy with a proprietary NAV technology platform featuring exclusive worldwide rights to over 100 AAV vectors. The company is developing multiple clinical-stage product candidates including RGX-314 for wet AMD, RGX-501 for HoFH, and RGX-111 for MPS I, with six programs in clinical trials and over 20 partnered programs in total.